Randomized trial explores serum IL-2's association with blood cell abnormalities in SLE, suggesting immune dysregulation implications.
Key Points
This study aims to investigate the relationship between serum IL-2 concentrations and hematological abnormalities in patients with systemic lupus erythematosus (SLE).
Recruited 235 patients with systemic lupus erythematosus (SLE).
Utilized complete blood counts and measured IL-2 levels using the ultrasensitive single-molecule array (Simoa) technique.
Applied multivariate linear and logistic regression analyses to evaluate associations.
Significant inverse associations found between serum IL-2 levels and hemoglobin, hematocrit, and total leukocyte counts (p<0.05).
IL-2 was associated with increased odds of anemia (OR, 2.3; 95% CI, 1.5-3.5; p<0.01), leukopenia (OR, 1.9; 95% CI, 1.2-3.0; p=0.02), and lymphopenia (OR, 2.0; 95% CI, 1.3-3.1; p=0.03) after adjustments.
No association was noted with neutropenia or thrombocytopenia.